Cryptosporidiosis is a debilitating diarrheal disease in young children in developing countries. The absence of effective treatments or vaccines makes this infection very difficult to manage in susceptible populations.
KEYWORDS: CRISPR/Cas9, active-site mutant, cryptosporidiosis, oocyst shedding, pathogenesis, sexual development
ABSTRACT
The apicomplexan parasite Cryptosporidium parvum contains an expanded family of 22 insulinase-like proteases (INS), a feature that contrasts with their otherwise streamlined genome. Here, we examined the function of INS1, which is most similar to the human insulinase protease that cleaves a variety of small peptide substrates. INS1 is an M16A clan member and contains a signal peptide, an N-terminal domain with the HXXEH active site, followed by three inactive domains. Unlike previously studied C. parvum INS proteins that are expressed in sporozoites and during merogony, INS1 was expressed exclusively in macrogamonts, where it was localized in small cytoplasmic vesicles. Although INS1 did not colocalize with the oocyst wall protein recognized by the antibody OW50, immune-electron microscopy indicated that INS1 resides in small vesicles in the secretory system. Notably, these small INS1-positive vesicles were often in close proximity to large OW50-positive vacuoles resembling wall-forming bodies, which contain precursors for oocyst wall formation. Genetic deletion of INS1, or replacement with an active-site mutant, resulted in lower formation of macrogamonts in vitro and reduced oocyst shedding in vivo. Our findings reveal that INS1 functions in the formation or maturation of macrogamonts and that its loss results in attenuated virulence in immunocompromised mice.
INTRODUCTION
Cryptosporidium spp. are apicomplexan parasites that cause diarrheal disease in humans and animals. Human infection is primarily caused by two species, Cryptosporidium parvum, which also infects agricultural ruminant animals and is zoonotic, and C. hominis, which is spread human to human (1). Cryptosporidiosis was recognized as one of the top three causes of severe diarrhea in children younger than 2 years of age in developing countries, as reported by the Global Enteric Multi-Center Study (2). Infection in early life is also associated with lasting defects in development even after infections subside (3). Nitazoxanide is the only FDA-approved drug for the treatment of cryptosporidiosis. However, it has a limited effect in immunocompromised individuals and is not approved for use in children under the age of two (4). There are currently no effective vaccines for C. parvum, and fundamental studies on parasite biology and host-pathogen interactions are needed to identify potential therapeutic and vaccine targets.
The entire life cycle of Cryptosporidium occurs in a single host, leading to efficient fecal-oral transmission (5). Following the ingestion of oocysts, sporozoites emerge and invade intestinal epithelial cells, where they develop in a unique vacuole formed at the apex of the host cell (6). The parasite initially grows as a trophozoite before undergoing multiple rounds of asexual replication during merogony (7, 8). The parasite then differentiates to the sexual phase and develops as macrogamonts or microgamonts that begin appearing after 44 to 48 h postinfection (hpi) (7, 8). However, in transformed cell lines grown in vitro, the infection does not progress and parasite numbers gradually decline (9). Comparison of in vitro cultures in adenocarcinoma cell lines to the developmental process that occurs in the intestine of mice revealed that the block to complete development in vitro is due to a lack of fertilization despite the fact that both gametocyte forms develop normally (7).
Biological investigations of Cryptosporidium have been hampered by limitations in experimental platforms for in vitro growth. Despite this limitation, in vitro propagation systems have been used to generate antibodies that identify different stages of C. parvum (10), leading to a better understanding the life cycle (8). Recent developments have also provided systems that allow complete development of infectious oocysts in stem cell-derived cultures in vitro (11, 12). Finally, advances in CRISPR/Cas9 technology have allowed genetic modification in C. parvum to tag genes for localization and disrupt them to study function (13). Despite these advances, we lack an understanding of the function of most genes in Cryptosporidium, many of which have no orthologues outside the genus or are specific for the phylum Apicomplexa (14, 15).
The genome of C. parvum is highly streamlined, with short intergenic regions, limited introns, and the loss of many metabolic pathways (16). Greater than 98% of genes in C. parvum are present as a single copy, and only a limited number of multigene families include insulinase-like proteases (INS), predicted secretory proteins containing the amino acid sequence MEDLE, and mucin-type glycoproteins (17). INS proteins belong to the M16 family of metallopeptidases that play diverse roles in cells, and they can be found in the cytosol, organelles, and even the cell surface (18). M16 metalloproteases typically bind zinc as part of their active site (HXXEH), and they cleave short polypeptides, the size of which is constrained by a conserved small barrel fold that forms the catalytic chamber (19). The apicomplexan parasite Toxoplasma gondii contains ∼50 metalloproteases, including 11 members of the M16 clan (20), several of which are found in secretory organelles implicated in host cell interactions (21, 22). In Plasmodium falciparum, the M16 metalloprotease falcilysin participates in both hemoglobin degradation and the processing of transit peptides for apicoplast proteins (23, 24). Similarly, other M16 family members are known for their roles in processing transit peptides for mitochondria and chloroplasts (18).
The C. parvum genome contains 22 members of the M16 family of metallopeptidases. Ten of these contain the active site HXXEH, indicating they act as enzymes in the parasite, although none of their substrates have been defined. Previous studies have shown that antibodies against INS20-19 (although originally annotated as two genes, later assemblies collapsed these into a single gene), INS15, or INS5 inhibit parasite invasion of host cells in vitro, suggesting they are involved in processing substrates important for host cell recognition or entry (25–27). In the present study, we focused on INS1, which is present among all Cryptosporidium spp. INS1 is a classic M16A family member with one active functional motif, HXXEH, followed by three inactive domains. We demonstrate that INS1 is expressed exclusively in macrogamonts of C. parvum, where it localizes to small transport vesicles. Deletion of INS1, or replacement with an inactive-site mutant, reduced formation of macrogamonts in vitro and reduced oocyst shedding and decreased virulence in immunocompromised mice.
RESULTS
Epitope tagging of C. parvum INS1.
We compared the sequences of the 22 members of the M16 metalloprotease family present in C. parvum using a neighbor-joining phylogenetic analysis. For comparison, we also included the human insulinase gene IDE (P14735). Phylogenetic analysis indicated that INS1, encoded by the cgd1_1680 gene, is most similar to IDE (Fig. 1A). INS1 contains a signal peptide and has four domains, one active domain containing the zinc-binding motif HLIEH and three inactive domains, consistent with INS1 belonging to the M16A clan (Fig. 1B). To investigate the cellular localization of INS1, we used CRISPR/Cas9 genome editing to tag INS1 with a triple hemagglutinin (3HA) epitope tag at the C terminus. The tagging construct also contained a selection cassette consisting of nanoluciferase (Nluc) cotranscribed with neomycin resistance (Neor) driven by an enolase promoter (13) (Fig. 1C). Similar to methods described previously, the Nluc and Neo proteins were separated by a split peptide motif (P2A) (12). This tagging construct was cotransfected with a CRISPR/Cas9 plasmid containing a single guide RNA sequence (sgRNA) located in the C terminus of the gene. To create parasites with INS1 fused to green fluorescent protein (GFP), we replaced the 3HA tag with GFP and used the same INS1 sgRNA plasmid (Fig. 1D).
Generation of stable transgenic INS1 parasites.
Excysted sporozoites were electroporated with INS1-3HA-Nluc-P2A-neo tagging plasmid and CRISPR/Cas9 plasmid containing the INS1 sgRNA. Following electroporation, sporozoites were used to infect Ifngr1−/− mice. Oocyst shedding reached a peak level 13 days postinfection (dpi), and all of the mice succumbed to infection by day 15, indicating the tagged line was not attenuated (see Fig. S1 in the supplemental material). Feces were collected from the first round of mice, and a slurry was gavaged into a group of Nod scid gamma (NSG) mice to obtain the larger numbers of transgenic oocysts for purification. All mice were treated with 16 g/liter paromomycin in drinking water for selection of stable transgenic parasites (Fig. 2A), as described previously (13). The signal of luminescence from the nLuc gene increased in fecal pellets from 6 dpi (days postinfection), with a peak value on 12 dpi (Fig. 2C). Quantification of oocysts in feces by qPCR paralleled the increase in luciferase activity (Fig. 2D). PCR analysis of oocysts collected from the mice confirmed that the INS1-3HA tagging cassette had correctly inserted into the INS1 locus, as shown using diagnostic primers that only amplify from the correct transgenic arrangement (Fig. 2B and E). To obtain a tagged INS1-GFP strain, we used the same strategy to amplify the INS1-GFP transgenic parasites. In the first round of infection in Ifngr1−/− mice, all of the animals succumbed by day 15, indicating the tagged line was not attenuated (Fig. S1). In the second round of amplification in NSG mice, luminescence and oocyst numbers measured from infected mouse feces increased on 6 dpi and remained elevated 1 month (Fig. 2G and H). PCR analysis confirmed that the INS1-GFP strain had correctly inserted into the INS1 locus (Fig. 2F and I). Fecal pellets were collected every day from 12 to 30 dpi for purification of transgenic parasites.
INS1 is expressed in macrogamonts.
To examine the expression of INS1 during intracellular development of C. parvum in vitro, we infected HCT-8 cells with wild-type oocysts and tested expression by reverse transcription-quantitative PCR (RT-qPCR) at different time points. We used two slightly different sets of RNA samples designed to cover the time range of the development of asexual and sexual stages, as described previously (8). The INS1 gene showed no transcription before 30 h postinfection (hpi) but was upregulated at 36 hpi and reached the highest level at 48 hpi before declining at 72 hpi (Fig. 3A). The sexual stages of C. parvum first appear ∼36 hpi (7, 8), and the positive signal for INS1 at this time point indicates that INS1 was expressed in either macrogamonts or microgamonts. To visualize the stage-specific expression and localization of INS1, we performed immunofluorescence assays (IFA) using INS1-3HA and INS1-GFP transgenic parasites. Neither the anti-HA antibody nor anti-GFP antibody detected any staining above background in asexual stages of C. parvum, consistent with the very low level of transcription of INS1 during these stages. Instead, INS1 was only detected in the macrogamont stage, where it appeared as punctate staining, while microgamonts remained negative (Fig. 3B and C).
Only a limited number of stage-specific proteins have been characterized in C. parvum, therefore we investigated two antibodies that have been previously shown to detect proteins that are expressed in macrogamonts. The punctate structures stained positively for INS1 did not colocalize with monoclonal antibody (MAb) 4D8, which recognizes a prominent filament structure of macrogamonts (10) (Fig. 4A). We also examined costaining with MAb OW50, which stains cytoplasmic inclusions called wall-forming bodies that are released to form the oocyst wall (28). INS1 was in clusters distinct from those of OW50; however, these were often in close proximity to each other (Fig. 4B). To explore the ultrastructural localization of INS1, INS1-GFP transgenic parasites were examined by immunoelectron microscopy. INS1 was located in small vesicles within macrogamonts, and these positive compartments were often in proximity to large electron-dense vesicles (Fig. 4C). Based on its timing of expression and localization, these findings suggest that INS1 plays some role in the development of macrogamonts.
Decreased oocyst shedding in Δins1 parasites.
To investigate INS1 function in C. parvum, we generated INS1 knockout (Δins1) parasites using CRISPR/Cas9. The INS1 gene was replaced with an mCherry expression cassette driven by the C. parvum actin promoter in a construct that also contained the Nluc-P2A-neoR selection marker described above (Fig. 5A). To ensure complete removal of the INS1 gene, we used two sgRNA sequences to degenerate double-stranded DNA breaks that flank the gene (Fig. 5A). Sporozoites were electroporated with the INS1-mCh-Nluc-P2A-neo-INS1 plasmid and a CRISPR/Cas9 plasmid containing the two INS1 sgRNAs (Fig. 5A). Transfected sporozoites were gavaged into a group of Ifngr1−/− mice treated with 16 g/liter paromomycin in the drinking water. Unlike the tagged lines described above, the knockout line was attenuated, and none of the Ifngr1−/− mice succumbed over a 30-day period (Fig. S1). Moreover, the peak leak level of oocyst shedding by the knockout line was 3.5-fold lower than that of the GFP-tagged line at 9 dpi (Fig. S1). After 13 dpi, the feces containing the Δins1 oocysts were collected and gavaged into a group of immunocompromised mice. For this second-round infection, we were interested in confirming the attenuation of this line, so we used Ifng−/− (GKO) mice, which, like Ifngr1−/− mice, are highly sensitive to C. parvum infection (Fig. 5C). PCR analysis confirmed that oocysts shed by GKO mice were Δins1 parasites based on correct 5′ and 3′ flanking sequences created by the loss of the INS1 gene and insertion of the mCherry expression cassette in its place (Fig. 5D). Additionally, primers to the open reading frame of INS1 failed to amplify a product from the knockout line, although they easily detected the expected fragments from wild-type parasites (Fig. 5D).
We then tracked the expansion of the Δins1 parasites by luciferase measurements and oocyst shedding in the feces in the second round of mice. Both luminescence values and oocyst shedding increased at 6 dpi and reached the peak at 12 dpi (Fig. 6A). Moreover, all mice infected by Δins1 parasites survived the infection and continued to shed oocysts for as long as 1 month, the longest time point we tracked (Fig. 6B).
INS1 requires active protease activity for function.
We further tested whether INS1 requires its protease activity for function. INS1 contains the active-site HLIEH that is a conserved motif in M16 metalloproteases. We used CRISPR/Cas9 genome editing to alter the INS1 active site from HLIEH to AAAAA while also adding a C-terminal 3HA tag (Fig. 5B). The replacement of the endogenous locus with this active-site mutant template (INS1m) was guided by two sgRNA sequences located in the N terminus and 3′-untranslated region (UTR) of the gene (Fig. 5B). Sporozoites were electroporated with the INS1(mu)-3HA-Nluc-P2A-neo plasmid, and a CRISPR/Cas9 plasmid containing two INS1 gRNAs and oocysts were amplified as before. Similar to the Δins1 knockout, this active-site mutant line was attenuated, and none of the Ifngr1−/− mice succumbed over a 30-day period (Fig. S1). Moreover, the peak leak level of oocyst shedding by the mutant line occurred much later, at day 18, and was 26-fold lower than that of the GFP-tagged line that peaked at day 13 (Fig. S1). To confirm this attenuation, we used GKO mice for the second round of infection. PCR analysis demonstrated that oocysts shed by GKO mice contained the correct 5′ and 3′ insertions of the repair template integrated into the INS1 locus (Fig. 5E). Sanger DNA sequencing of PCR products amplified from INS1m parasites confirmed the replacement of the wild-type copy with the mutated active site in oocysts recovered from the GKO mice (Fig. 5F). The INS1m active-site mutants grew with slower kinetics than wild-type parasites, and all infected mice survived infection for as long as 1 month, similar to the Δins1 parasites described above (Fig. 6C and D).
Inhibition of macrogamont maturation in Δins1 and INS1m parasites in vitro.
To test the growth abilities of the knockout and active-site mutants in vitro, we infected HCT-8 cells with 104 oocysts of each of the mutant versus wild-type parasites and returned them to culture to allow development. After 48 hpi, we fixed cells and labeled them with MAb 4D8 to detect macrogamonts as well as pan-Cp antibody to detect all stages (Fig. 6E). Life cycle stages were then defined on the following bases: meronts were classified by one to eight nuclei but no 4D8 labeling, macrogamonts were classified by a single nucleus and were positive 4D8 labeling, and microgamonts were classified as having 16 nuclei but no 4D8 labeling. Wild-type parasite cultures showed 55% of parasites were meronts, 38% of parasites were macrogamonts, and 7% of parasites were microgamonts at 48 hpi. In contrast, Δins1 cultures showed significantly fewer macrogamonts (24%) with an increase in the proportion of meronts (71%) (Fig. 6F). Similarly, HCT-8 cultures infected with the active-site INS1m mutant parasites showed significantly fewer macrogamonts (28%) with an increase in the proportion of meronts (68%) (Fig. 6F). Collectively, these findings indicate that INS1 functions to facilitate macrogamont development, and in its absence, oocyst shedding is reduced in immunocompromised mice.
DISCUSSION
The C. parvum genome contains an expanded family of 22 M16 metalloproteases, the majority of which have unknown functions. Here, we focused on INS1, which is a clan M16A metalloprotease most similar to human insulinase. INS1 contains a signal peptide and an active domain containing the catalytic site HXXEH followed by several inactive domains. Unlike previously described INS proteins that are expressed early in development in C. parvum, INS1 was expressed exclusively in macrogamonts, where it localized to small vesicular structures in the cytosol. Deletion of INS1, or replacement with an active-site mutant, resulted in reduced formation of macrogametocytes in vitro and lower oocyst shedding in vivo. Our studies reveal that INS1 likely participates in macrogamont formation, and in its absence the parasite forms fewer oocysts in vivo and is attenuated in immunocompromised mice.
Metalloproteases are widespread in biology and have been classified into 16 clans that are summarized in the MEROPS database (https://www.ebi.ac.uk/merops/). M16 metalloproteases are characterized by the presence of a zinc-binding motif consisting of the sequence HXXEH (20). M16A and M16C family members contain four domains, only one of which contains the active catalytic site (20). The best known M16 protease is human insulinase, which cleaves a variety of small peptides in different types of cells, consistent with the multiple roles of this enzyme (29). Apicomplexan parasites contain numerous M16 metalloproteases, although their roles have only partially been investigated. Two M16C proteases have been described in Plasmodium falciparum. Falcilysin is involved in hemoglobin degradation and processing of the apicoplast import transit peptides (23, 24), an activity that is also catalyzed by P. falciparum SPP (30). Toxoplasma gondii contains 11 M16 orthologues, and several M16A enzymes found in secretory compartments have been previously studied (20). Toxolysin 1 is found in rhoptries (21), while toxolysin 4 is found in micronemes (22). Both proteases are themselves processed during maturation, but their substrates and the roles these proteases play in their respective secretory compartments are undefined. Toxolysin 4 is refractory to gene disruption (22), while the loss of toxolysin 1 has no effect on growth in vitro or virulence in vivo (21). Toxolysin 3, encoded by TGME49_257010, is most similar to INS1 by sequence homology. Toxolysin 3 is annotated as a sporozoite development protein (https://toxodb.org/toxo/app), as it is highly expressed in unsporulated and sporulated oocysts (31). In contrast, INS1 is expressed exclusively in macrogamonts, indicating that these M16 metalloproteases have different biological roles.
Of the 22 M16 metalloproteases encoded by the C. parvum genome, 18 of them belong to the M16A family, and several of these have previously been studied, including INS5, INS15, and INS20-19. INS15 and INS20-19 contain signal peptides, suggesting they are in the secretory pathway, while INS5 does not have a predicted signal peptide (25–27). INS20-19 is expressed in sporozoites and localized to an apical compartment (25), while INS15 is expressed in a middle-anterior compartment in sporozoites and merozoites (26). In contrast, INS5 is expressed at lower levels in sporozoites and increases to a peak at 36 to 48 hpi (27). INS5 is present in a punctate pattern in sporozoites and during merogony (27). Antibodies to these proteins have been shown to inhibit parasite invasion in vitro (25–27), suggesting they play some role in processing or maturation of substrates involved in host cell recognition. Their similar expression pattern during the life cycle, secretory nature, and ability of antibodies against them to partially neutralize infection suggests that the above-mentioned paralogous INS proteins play partially redundant roles in interacting with the host cell. INS1 is a classic M16A protease containing a signal peptide and an HLIEH active motif in the N-terminal domain followed by three domains that lack this catalytic motif. INS1 has closely related orthologues in other Cryptosporidium spp. (32), suggesting it has a conserved function. However, unlike the INS proteins mentioned above, INS1 is not expressed in sporozoites or merozoites and, hence, is unlikely to function in interactions with the host cell during invasion. The phylogenetic analysis of INS genes in C. parvum identified several genes that are closely related to INS1. These include INS3 (encoded by cgd2_920), which is also more highly expressed in macrogamonts (7), although it does not contain a signal peptide, suggesting that it has a different role than INS1. Likewise, the related protein INS4 (encoded by cgd2_930), which is expressed much earlier at 24 hpi (7), also lacks a signal peptide, suggesting it has a different role than INS1.
INS1 was not detected in sporozoites or during merogony, but expression was strongly upregulated at 36 to 48 hpi, when the sexual stages are formed (8). Consistent with this pattern, previous studies have shown that INS1 and INS3 are highly expressed in macrogamonts in vivo and in in vitro culture (7). Tagging with the HA epitope or a GFP fusion indicated that INS1 is expressed exclusively in macrogamonts, where it is localized to small vesicular structures in the cytosol. INS1 was not colocalized with 4D8 antibody, which recognizes a unique striated fiber in macrogamonts (10). Additionally, INS1 only partially colocalized with OW50, which recognizes large punctate vesicles in the cytosol of macrogamonts and the wall in mature oocysts (12). When examined by immunoelectron microscopy, INS1 was found in small vesicular structures that were often adjacent to large electron-dense vesicles. These large vesicles resemble wall-forming bodies, which are large cytoplasmic vesicles that contain proteins involved in the formation of the oocyst wall (33). Attempts to label OW50, a component of wall-forming bodies and the oocyst wall, in combination with INS1 by immunoelectron microscopy were not successful. Nonetheless, the proximity of small vesicles containing INS1 to the larger vesicles suggests that INS1 is involved in the processing or trafficking of constituents of the wall-forming body vesicles and that disruption of this process impairs macrogamont maturation and subsequent oocyst formation. Like other insulinase enzymes (19), INS1 is predicted to have a small folded barrel containing the active site that is only capable of accommodating small peptides ranging from 3 to 6 kDa. As such, INS1 is likely to process small peptides, possibly resulting from trimming of secretory proteins by other peptidases in the secretory pathway.
The deletion of INS1, or replacement with the INS1m active-site mutant, did not affect asexual replication in vitro or completely block development, indicating that INS1 is not essential for growth. Instead, the loss of INS1 resulted in the reduced formation of macrogamonts in vitro and lower oocyst shedding in vivo. In human insulinase, replacement of E111 in the HXXEH active site with Q111 inactivates catalysis (34, 35). Similarly, the insulinase homologue Iph1 in yeast loses catalytic activity when the E71 active site is changed to D71 (36). Although we have not formally demonstrated that the INS1m enzyme has lost catalytic activity, the complete replacement of the HXXEH site with AAAAA is consistent with that interpretation. Hence, the similar phenotypes of the Δins1 strain and the INS1m active-site mutants suggest that the observed phenotype of the knockout is due to the loss of catalytic activity. We also observed that the defect in the INS1m active site was approximately 2 times more severe in terms of reduced oocyst shedding than the complete deletion, suggesting the expression of an inactive enzyme has a dominant-negative effect that is greater than the loss of the enzyme. Both the Δins1 and the INS1m active-site mutants were less virulent in Ifngr1−/− and GKO mice, and reduced oocyst shedding was associated with survival beyond 12 days, when mice infected with epitope-tagged or GFP-tagged parasites succumbed to infection. The lower virulence of the INS1 mutants is likely an indirect consequence of reduced macrogamonts, fewer oocysts, and possibly fewer thin-walled oocysts that are thought to result in reinfection, since pathology caused by the infection is normally associated with multiple rounds of merogony.
Our studies reveal that INS1 participates in macrogamont formation or maturation and that the catalytic function of INS1 is necessary for the optimal formation of oocysts. Cryptosporidium oocysts are comprised of an inner layer of glycoproteins, called oocyst wall proteins (OWPs), that are rich in cysteine and histidine (37) in addition to an outer acid-fast lipid layer (38). The process by which these components are synthesized, exported, and assembled into layers in the wall is largely unknown. In addition to providing insight into the development of macrogamonts, further study of INS1, and related peptidases, may reveal further insights into the process of oocyst wall formation.
MATERIALS AND METHODS
Animal studies.
Animal studies on mice were approved by the Institutional Animal Studies Committee (School of Medicine, Washington University in St. Louis). The Ifngr1−/− mice (003288; Jackson Laboratories), Ifng−/− mice (referred to as GKO) (002287; Jackson Laboratories), and Nod scid gamma mice (referred to as NSG) (005557; Jackson Laboratories) were bred in-house at Washington University School of Medicine and were separated by sex after weaning. Ifngr1−/− and GKO mice raised in our facility are highly susceptible to the strain of C. parvum used here, and they shed high numbers of oocysts and routinely die within 10 to 12 dpi. As such, they are used to amplify transgenic strains following initial transfection of sporozoites. In contrast, NSG mice are more resistant and can be used for prolonged oocyst shedding, which occurs are lower peak levels. Mice were reared in a specific-pathogen-free facility on a 12-h:12-h light-dark cycle and water ad libitum. For selection and amplification of transgenic C. parvum parasites, 8- to 12-week-old mice were used and water was replaced with filtered tap water containing 16 g/liter paromomycin sulfate salt (Sigma). During the course of infection, animals that lost more than 20% of their body weight or became nonambulatory were humanely euthanized.
Phylogenetic analysis.
The amino acid sequences of INS in Cryptosporidium parvum were extracted from CryptoDB (https://cryptodb.org/cryptodb/app), and the human insulinase was extracted from UniProt (https://www.uniprot.org). The phylogenetic tree was constructed based on these sequences. MUSCLE was used to align the concatenated sequences. Phylogenetic trees based on maximum likelihood were constructed with 1,000 replications for bootstrapping.
Primers.
All primers were synthesized by Integrated DNA Technologies and are listed in Table S1 in the supplemental material.
Oocyst preparation and excystation.
Cryptosporidium parvum oocysts were obtained from the Witola laboratory (University of Illinois at Urbana-Champaign). The C. parvum isolate (AUCP-1) was maintained by repeated passage in male Holstein calves and purified from fecal material, as described previously (39). Purified oocysts were stored at 4°C in 50 mM Tris-10 mM EDTA (pH 7.2) for up to 6 months before use. Before infection, 1 × 108 purified oocysts were diluted into 1 ml of Dulbecco’s phosphate-buffered saline (DPBS; Corning Cellgro) and treated with 3 ml of 40% bleach (containing 8.25% sodium hypochlorite) for 10 min on ice. Oocysts were then washed 4 times in DPBS containing 1% (wt/vol) bovine serum albumin (BSA; Sigma) and resuspended in 1 ml DPBS with 1% BSA. For some experiments, oocysts were excysted prior to infection by incubating the oocysts with 0.75% (wt/vol) sodium taurocholate (Sigma) at 37°C for 60 min.
HCT-8 cell culture.
Human ileocecal adenocarcinoma cells (HCT-8 cells; ATCC CCL-244) were cultured in RPMI 1640 medium (ATCC modification; Gibco) supplemented with 10% fetal bovine serum. The HCT-8 cells were determined to be mycoplasma negative using the e-Myco plus kit (Intron Biotechnology).
Gene expression analysis.
HCT-8 cells were grown on 6-well culture plates and incubated 24 h before infection. Monolayers were infected with excysted sporozoites and washed twice with DPBS at 2 hpi, and fresh HCT-8 medium then was added. RNA was collected from three wells per time point in RLT buffer (Qiagen) plus 1% β-mercaptoethanol, homogenized using a QIAshredder column (Qiagen), and then stored at −80°C until further processing. RNA was extracted using the RNeasy minikit (Qiagen), treated with the DNA-free DNA removal kit (Thermo Fisher Scientific), and converted to cDNA using the SuperScript VILO cDNA synthesis kit (Thermo Fisher Scientific). Reverse transcription quantitative PCR (RT-qPCR) was performed using a QuantStudio 3 real-time PCR system (Thermo Fisher Scientific) with SYBR green JumpStart Taq ReadyMix (Sigma) using primers listed in Table S1. The following conditions were used for RT-qPCR: priming at 95°C for 2 min, followed by 40 cycles of denaturing at 95°C for 10 s, annealing at 60°C for 20 s, and extension at 72°C for 30 s, followed by a melt curve analysis to detect nonspecific amplification. Relative gene expression was calculated with the ΔΔCT method (40) using C. parvum 18S rRNA as the reference gene.
Gene tagging using CRISPR/Cas9.
To provide a single guide RNA (sgRNA) plasmid for INS1, the plasmid pACT1:Cas9-GFP, U6:sgINS1 was generated by replacing the TK sgRNA in pACT1:Cas9-GFP, U6:sgTK plasmid (12) with an sgRNA matching a region 158 bp before the stop codon in the INS1 gene (cgd1_1680), using Q5 site-directed mutagenesis (New England Biosciences). The INS1 sgRNA was designed using the eukaryotic pathogen CRISPR guide RNA/DNA design tool (http://grna.ctegd.uga.edu). To generate a tagging plasmid, a portion of the INS1 C terminus (253 bp) with the mutant protospacer adjacent motif (PAM) and INS1 3′UTR (117 bp) was amplified from C. parvum genome DNA. The triple hemagglutinin (3HA) epitope tag was amplified from pTUB1:YFP-mAID-3HA, DHFR-TS:HXGPRT (41). The previously described Nluc-P2A-neoR reporter including the pUC19 backbone was amplified from TK-GFP-Nluc-P2A-neo-TK plasmid (12). The tagging plasmid pINS1-3HA-Nluc-P2A-neo was then generated by Gibson assembly of the components listed above. To generate a C-terminal tag with a green fluorescent protein (GFP) tag, the plasmid pINS1-GFP-Nluc-P2A-neo was constructed by swapping the 3HA with GFP from TK-GFP-Nluc-P2A-neo-TK plasmid using Gibson assembly of PCR-amplified fragments.
Gene deletion using CRISPR/Cas9.
To provide a plasmid for gene deletion, a second sgRNA, U6:sgINS1(2), was inserted in the plasmid pACT1:Cas9-GFP, U6:sgINS1 to generate the plasmid pACT1:Cas9-GFP, dual, U6:sgINS1-KO. This plasmid contains two sgRNAs that flank the gene, one located at the C terminus of INS1, 158 bp before the stop codon, and one located at the N terminus of INS1, 55 bp after the promoter. The targeting plasmid pINS1-mCh-Nluc-P2A-neo-INS1 was made by replacing the UPRT homologous flanks with INS1 homologous flanks (770 bp upstream and 852 bp downstream of cgd1_1680) from UPRT-mCh-Nluc-P2A-neo-UPRT (12) using Gibson assembly of PCR-amplified fragments.
Generating point mutations using CRISPR/Cas9.
To generate an active-site mutant of INS1, the plasmid pACT1:Cas9-GFP, dual, U6:sgINS1-mu was generated by inserting two new sgRNAs in the pACT1:Cas9-GFP, U6:sgTK plasmid. This plasmid contains two sgRNAs that flank the gene, one located at the N terminus of INS1, 5 bp after the active site, and one is located at the 3′UTR of INS1, 3 bp after the stop codon. To generate the targeting plasmid, a portion of the C terminus INS1 homologous flanks with flanking regions before the active site (3,081 bp of cgd1_1680) and 117-bp INS1 3′UTR was amplified from C. parvum genome DNA, and PAM sequences were mutated to prevent recutting the repair DNA. The active site in INS1 HLIEH was then mutated to AAAAA using Q5 site-directed mutagenesis. The 3HA-Nluc-P2A-neoR reporter including the pUC19 backbone was amplified from INS1-3HA-Nluc-P2A-neo plasmid. The targeting plasmid pINS1(mu)-3HA-Nluc-P2A-neo was generated by Gibson assembly of the components listed above.
Transfection of C. parvum sporozoites.
Oocysts (1.25 × 107 per transfection) were excysted as described above, and sporozoites were pelleted by centrifugation and resuspended in SF buffer (Lonza) containing 50 μg of tagging or targeting plasmids and 30 μg CRISPR/Cas9 plasmid in a total volume of 100 μl. The mixtures were then transferred to a 100-μl cuvette (Lonza) and electroporated on an AMAXA 4D-Nucleofector system (Lonza) using program EH100. Electroporated sporozoites were transferred to cold DPBS and kept on ice before infecting mice.
Selection and amplification of transgenic parasites in immunodeficient mice.
Three Infgr1−/− mice were used for the first round of transgenic parasite selection. Each mouse was orally gavaged with 200 μl of saturated sodium bicarbonate 5 min prior to infection. Each mouse was then gavaged with 2.5 × 107 electroporated sporozoites. All mice received drinking water with 16 g/liter paromomycin continuously from the first day postinfection (dpi), based on previously published protocols (13). Fecal pellets were collected begin at 9 to 15 dpi, after which animals were euthanized by CO2 asphyxiation according to the animal protocol guidelines. Fecal pellets were stored at −80°C for qPCR or at 4°C for luciferase assays or for isolating oocysts for subsequent infections.
A second round of amplification was performed by orally gavaging 3 to 4 NSG mice (used for isolating tagged strains) or GKO mice (used for amplifying knockout or mutation lines) using a fecal slurry from round one mice described above. The fecal pellets were transferred to a 1.7-ml microcentrifuge tube, ground with a pestle, diluted by addition of 1 ml cold DPBS, vortexed for 30 s, and centrifuging at 200 rpm for 10 min to pellet large particulates. The supernatant was then diluted in DPBS to achieve a concentration of ∼2 × 104 oocysts in 200 μl DPBS and then gavaged into one mouse. Similar to round one, the mice infected in round two were treated with 16 g/liter paromomycin drinking water for the entirety of the experiment. Fecal pellets for qPCR and luciferase assay were collected every 3 days starting 3 dpi and fecal pellets for purification were collected every day starting at 12 dpi and stored at 4°C. For purification, fecal samples from all mice were pooled and oocysts extracted as previously described (42). Purified oocysts were stored in PBS at 4°C and used within 6 months of extraction.
Luciferase assay.
Luciferase assays were performed with the Nano-Glo Luciferase assay kit (Promega). Mouse fecal pellets were collected in 1.7-ml microcentrifuge tubes, ground with a pestle, and then 3-mm glass beads (Fisher Scientific) and 1 ml fecal lysis buffer (50 mM Tris pH 7.6, 2 mM DTT, 2 mM EDTA pH 8.0, 10% glycerol, 1% Triton X-100 prepared in water) (43) were added to the tube. Tubes were incubated at 4°C for 30 min, vortexed for 1 min, and then spun at 16,000 × g for 1 min to pellet debris. The 100-μl supernatant was added split between two wells of a 96-well white plate (Costar 3610), and then 100 μl of a 25:1 Nano-Glo Luciferase buffer to Nano-Glo Luciferase substrate mix was added to each well, and the plate was incubated for 3 min at room temperature. Luminescence values were read on a Cytation 3 cell imaging multi-mode reader (BioTek).
Fecal DNA extraction and quantification of oocysts.
DNA was extracted from fecal pellets using the QIAamp PowerFecal DNA kit (Qiagen) according to the manufacturer’s protocols. Oocyst numbers were quantified using qPCR with the C. parvum glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers (Table S1), as described previously (12). A standard curve for C. parvum genomic DNA was generated by purifying DNA from a known number of oocysts and creating a dilution series. Reactions were performed on a QuantStudio 3 real-time PCR system (Thermo Fisher) with the amplification conditions as previously described (12).
PCR identification of transgenic parasites.
To check for the successful insertion of the target sequence into the INS1 locus, PCR was performed on 1 μl purified fecal DNA using Q5 Hot Start high-fidelity 2× master mix (New England Biosciences) with primers listed in Table S1 at a final concentration of 500 nM each. PCRs were performed on a Veriti 96-well thermal cycler (Applied Biosystems) with the following cycling conditions: 98°C for 30 s, followed by 35 cycles of 98°C for 15 s, 60°C for 30 s, and 72°C for 2 min, with a final extension of 72°C for 2 min. PCR products were resolved on 1.0% agarose gel containing GelRed (diluted 1:10,000; Biotium) and imaged on a ChemiDoc MP imaging system (Bio-Rad).
Indirect immunofluorescence microscopy.
HCT-8 cells grown on coverslips were infected 24 h postseeding with 1 × 105 oocysts per well and then fixed with 4% formaldehyde at specific time points. The fixed samples were washed twice with DPBS and then permeabilized and blocked with DPBS containing 1% BSA and 0.1% Triton X-100 (Sigma). Primary antibodies were diluted in blocking buffer for staining: rat anti-HA was used at 1:500, rabbit anti-GFP was used at 1:1,000, MAb 4D8 (hybridoma supernatant) was used at 1:20, MAb OW50 (10) was used at 1:10, and pan-Cp (rabbit or rat polyclonal antibody) was used at 1:10,000. Cells were incubated with primary antibodies for 60 min at room temperature, washed three times with PBS, and then incubated for 60 min at room temperature in secondary antibodies conjugated to Alexa Fluor dyes (Thermo Fisher Scientific) diluted 1:1,000 in blocking buffer. Nuclear DNA was stained with Hoechst (Thermo Fisher Scientific) diluted 1:1,000 in blocking buffer for 15 min at room temperature and then mounted with Prolong Diamond antifade mountant (Thermo Fisher Scientific). Imaging was performed on a Zeiss Axioskop Mot Plus fluorescence microscope equipped with a 100×, 1.4-numeric-aperture Zeiss Plan Apochromat oil objective lens and an AxioCam MRm monochrome digital camera. Images were acquired using AxioVision software (Carl Zeiss Inc.) and manipulated in ImageJ or Photoshop.
Transmission electron microscopy.
HCT-8 cells were infected with INS1-GFP parasites for 48 h, and infected cells then were fixed in freshly prepared mixture of 4% paraformaldehyde and 0.05% glutaraldehyde (Polysciences Inc., Warrington, PA) in 100 mM piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES)–0.5 mM MgCl2 buffer (pH 7.2) for 60 min at 4°C. Samples were then embedded in 10% gelatin and infiltrated overnight with 2.3 M sucrose–20% polyvinyl pyrrolidone in PIPES–MgCl2 at 4°C. Samples were trimmed, frozen in liquid nitrogen, and sectioned with a Leica Ultracut UCT7 cryo-ultramicrotome (Leica Microsystems Inc., Bannockburn, IL). Ultrathin sections of 50 nm were blocked with 5% fetal bovine serum–5% normal goat serum for 30 min and subsequently incubated with rabbit anti-GFP antibody (Life Technologies Corp., Eugene, OR) for 60 min at room temperature. Following washes in block buffer, sections were incubated with goat anti-rabbit IgG (H+L) conjugated to 18-nm colloidal gold (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) for 60 min. Sections were stained with 0.3% uranyl acetate–2% methyl cellulose and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8 megapixel digital camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn, MA). All labeling experiments were conducted in parallel with controls omitting the primary antibody. These controls were consistently negative at the concentration of colloidal gold conjugated secondary antibodies used in these studies.
Quantification and statistical analysis.
All statistical analyses were performed in GraphPad Prism 8 (GraphPad Software) unless otherwise specified. When comparing the means of two groups at the same time point, we used an unpaired t test. For statistical analysis, P values of ≤0.05 were considered significant.
Data availability.
All of the data are found in the manuscript or supplemental material.
ACKNOWLEDGMENTS
We thank members of the Sibley laboratory for helpful comments, Lisa Funkhouser-Jones for providing cDNA samples, Soumya Ravindran for technical assistance, and Wandy Beatty, Microbiology Imaging Facility at Washington University in St. Louis, for performing the electron microscopy studies.
This work was partially supported by a grant from the China Scholarship Council to R.X., a grant from the 111 Project (D20008) to Y.F., and a grant from the National Institutes of Health (AI149309) to L.D.S.
Footnotes
Citation Xu R, Feng Y, Xiao L, Sibley LD. 2021. Insulinase-like protease 1 contributes to macrogamont formation in Cryptosporidium parvum. mBio 12:e03405-20. https://doi.org/10.1128/mBio.03405-20.
REFERENCES
- 1.Feng Y, Ryan UM, Xiao L. 2018. Genetic diversity and population structure of Cryptosporidium. Trends Parasitol 34:997–1011. doi: 10.1016/j.pt.2018.07.009. [DOI] [PubMed] [Google Scholar]
- 2.Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acacio S, Biswas K, O'Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM. 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382:209–222. doi: 10.1016/S0140-6736(13)60844-2. [DOI] [PubMed] [Google Scholar]
- 3.Kotloff KL. 2017. The burden and etiology of diarrheal illness in developing countries. Pediatr Clin North Am 64:799–814. doi: 10.1016/j.pcl.2017.03.006. [DOI] [PubMed] [Google Scholar]
- 4.Checkley W, White AC, Jr, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, Fayer R, Griffiths JK, Guerrant RL, Hedstrom L, Huston CD, Kotloff KL, Kang G, Mead JR, Miller M, Petri WA, Jr, Priest JW, Roos DS, Striepen B, Thompson RC, Ward HD, Van Voorhis WA, Xiao L, Zhu G, Houpt ER. 2015. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for Cryptosporidium. Lancet Infect Dis 15:85–94. doi: 10.1016/S1473-3099(14)70772-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bouzid M. 2013. Cryptosporidium pathogenicity and virulence. Clin Microbiol Rev 26:115–134. doi: 10.1128/CMR.00076-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Current WL, Reese NC. 1986. A comparison of endogenous development of three isolates of Cryptosporidium in suckling mice. J Protozool 33:98–108. doi: 10.1111/j.1550-7408.1986.tb05567.x. [DOI] [PubMed] [Google Scholar]
- 7.Tandel J, English ED, Sateriale A, Gullicksrud JA, Beiting DP, Sullivan MC, Pinkston B, Striepen B. 2019. Life cycle progression and sexual development of the apicomplexan parasite Cryptosporidium parvum. Nat Microbiol 4:2226–2236. doi: 10.1038/s41564-019-0539-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Funkhouser-Jones LJ, Ravindran S, Sibley LD, Weiss LM. 2020. Defining stage-specific activity of potent new inhibitors of Cryptosporidium parvum growth in vitro. mBio 11:e00052-20. doi: 10.1128/mBio.00052-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Arrowood MJ. 2002. In vitro cultivation of Cryptosporidium species. Clin Microbiol Rev 15:390–400. doi: 10.1128/cmr.15.3.390-400.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wilke G, Ravindran S, Funkhouser-Jones L, Barks J, Wang Q, VanDussen KL, Stappenbeck TS, Kuhlenschmidt TB, Kuhlenschmidt MS, Sibley LD. 2018. Monoclonal antibodies to intracellular stages of Cryptosporidium parvum define life cycle progression in vitro. mSphere 3:e00124-18. doi: 10.1128/mSphere.00124-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Heo I, Dutta D, Schaefer DA, Iakobachvili N, Artegiani B, Sachs N, Boonekamp KE, Bowden G, Hendrickx APA, Willems RJL, Peters PJ, Riggs MW, O'Connor R, Clevers H. 2018. Modelling Cryptosporidium infection in human small intestinal and lung organoids. Nat Microbiol 3:814–823. doi: 10.1038/s41564-018-0177-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Wilke G, Funkhouser-Jones LJ, Wang Y, Ravindran S, Wang Q, Beatty WL, Baldridge MT, VanDussen KL, Shen B, Kuhlenschmidt MS, Kuhlenschmidt TB, Witola WH, Stappenbeck TS, Sibley LD. 2019. A stem-cell-derived platform enables complete Cryptosporidium development in vitro and genetic tractability. Cell Host Microbe 26:123–134. doi: 10.1016/j.chom.2019.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Vinayak S, Pawlowic MC, Sateriale A, Brooks CF, Studstill CJ, Bar-Peled Y, Cipriano MJ, Striepen B. 2015. Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum. Nature 523:477–480. doi: 10.1038/nature14651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA, Deng M, Liu C, Widmer G, Tzipori S, Buck GA, Xu P, Bankier AT, Dear PH, Konfortov BA, Spriggs HF, Iyer L, Anantharaman V, Aravind L, Kapur V. 2004. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 304:441–445. doi: 10.1126/science.1094786. [DOI] [PubMed] [Google Scholar]
- 15.Xu P, Widmer G, Wang Y, Ozaki LS, Alves JM, Serrano MG, Puiu D, Manque P, Akiyoshi D, Mackey AJ, Pearson WR, Dear PH, Bankier AT, Peterson DL, Abrahamsen MS, Kapur V, Tzipori S, Buck GA. 2004. The genome of Cryptosporidium hominis. Nature 431:1107–1112. doi: 10.1038/nature02977. [DOI] [PubMed] [Google Scholar]
- 16.Rider SD, Jr, Zhu G. 2010. Cryptosporidium: genomic and biochemical features. Exp Parasitol 124:2–9. doi: 10.1016/j.exppara.2008.12.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Xu Z, Guo Y, Roellig DM, Feng Y, Xiao L. 2019. Comparative analysis reveals conservation in genome organization among intestinal Cryptosporidium species and sequence divergence in potential secreted pathogenesis determinants among major human-infecting species. BMC Genomics 20:406. doi: 10.1186/s12864-019-5788-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Rawlings ND, Waller M, Barrett AJ, Bateman A. 2014. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 42:D503–D509. doi: 10.1093/nar/gkt953. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Aleshin AE, Gramatikova S, Hura GL, Bobkov A, Strongin AY, Stec B, Tainer JA, Liddington RC, Smith JW. 2009. Crystal and solution structures of a prokaryotic M16B peptidase: an open and shut case. Structure 17:1465–1475. doi: 10.1016/j.str.2009.09.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Escotte-Binet S, Huguenin A, Aubert D, Martin AP, Kaltenbach M, Florent I, Villena I. 2018. Metallopeptidases of Toxoplasma gondii: in silico identification and gene expression. Parasite 25:26. doi: 10.1051/parasite/2018025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hajagos BE, Turetzky JM, Peng ED, Cheng SJ, Ryan CM, Souda P, Whitelegge JP, Lebrun M, Dubremetz JF, Bradley PJ. 2012. Molecular dissection of novel trafficking and processing of the Toxoplasma gondii rhoptry metalloprotease toxolysin-1. Traffic 13:292–304. doi: 10.1111/j.1600-0854.2011.01308.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Laliberte J, Carruthers VB. 2011. Toxoplasma gondii toxolysin 4 is an extensively processed putative metalloproteinase secreted from micronemes. Mol Biochem Parasitol 177:49–56. doi: 10.1016/j.molbiopara.2011.01.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Eggleson KK, Duffin KL, Goldberg DE. 1999. Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. J Biol Chem 274:32411–32417. doi: 10.1074/jbc.274.45.32411. [DOI] [PubMed] [Google Scholar]
- 24.Ponpuak M, Klemba M, Park M, Gluzman IY, Lamppa GK, Goldberg DE. 2007. A role for falcilysin in transit peptide degradation in the Plasmodium falciparum apicoplast. Mol Microbiol 63:314–334. doi: 10.1111/j.1365-2958.2006.05443.x. [DOI] [PubMed] [Google Scholar]
- 25.Zhang S, Wang Y, Wu H, Li N, Jiang J, Guo Y, Feng Y, Xiao L. 2019. Characterization of a species-specific insulinase-like protease in Cryptosporidium parvum. Front Microbiol 10:354. doi: 10.3389/fmicb.2019.00354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Xu R, Guo Y, Li N, Zhang Q, Wu H, Ryan U, Feng Y, Xiao L. 2019. Characterization of INS-15, a metalloprotease potentially involved in the invasion of Cryptosporidium parvum. Microorganisms 7:452. doi: 10.3390/microorganisms7100452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ni N, Jia R, Guo Y, Li N, Wu H, Feng Y, Xiao L. 2020. Expression and functional studies of INS-5, an insulinase-like protein in Cryptosporidium parvum. Front Microbiol 11:719. doi: 10.3389/fmicb.2020.00719. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Sterling CR, Arrowood MJ. 1986. Detection of Cryptosporidium sp. infections using a direct immunofluorescent assay. Pediatr Infect Dis 5:S139–S142. doi: 10.1097/00006454-198601001-00022. [DOI] [PubMed] [Google Scholar]
- 29.Bondy CA, Zhou J, Chin E, Reinhardt RR, Ding L, Roth RA. 1994. Cellular distribution of insulin-degrading enzyme gene expression. Comparison with insulin and insulin-like growth factor receptors. J Clin Investig 93:966–973. doi: 10.1172/JCI117103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.van Dooren GG, Su V, D'Ombrain MC, McFadden GI. 2002. Processing of an apicoplast leader sequence in Plasmodium falciparum and the identification of a putative leader cleavage enzyme. J Biol Chem 277:23612–23619. doi: 10.1074/jbc.M201748200. [DOI] [PubMed] [Google Scholar]
- 31.Fritz HM, Buchholz KR, Chen X, Durbin-Johnson B, Rocke DM, Conrad PA, Boothroyd JC. 2012. Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. PLoS One 7:e29998. doi: 10.1371/journal.pone.0029998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Liu S, Roellig DM, Guo Y, Li N, Frace MA, Tang K, Zhang L, Feng Y, Xiao L. 2016. Evolution of mitosome metabolism and invasion-related proteins in Cryptosporidium. BMC Genomics 17:1006. doi: 10.1186/s12864-016-3343-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Spano F, Puri C, Ranucci L, Putignani L, Crisanti A. 1997. Cloning of the entire COWP gene of Cryptosporidium parvum and ultrastructural localization of the protein during sexual parasite development. Parasitology 114:427–437. doi: 10.1017/S0031182096008761. [DOI] [PubMed] [Google Scholar]
- 34.Perlman RK, Gehm BD, Kuo WL, Rosner MR. 1993. Functional analysis of conserved residues in the active site of insulin-degrading enzyme. J Biol Chem 268:21538–21544. doi: 10.1016/S0021-9258(20)80575-4. [DOI] [PubMed] [Google Scholar]
- 35.Shen Y, Joachimiak A, Rosner MR, Tang WJ. 2006. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 443:870–874. doi: 10.1038/nature05143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Beuzelin C, Evnouchidou I, Rigolet P, Cauvet-Burgevin A, Girard PM, Dardalhon D, Culina S, Gdoura A, van Endert P, Francesconi S. 2013. Deletion of the fission yeast homologue of human insulinase reveals a TORC1-dependent pathway mediating resistance to proteotoxic stress. PLoS One 8:e67705. doi: 10.1371/journal.pone.0067705. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Chatterjee A, Banerjee S, Steffen M, O'Connor RM, Ward HD, Robbins PW, Samuelson J. 2010. Evidence for mucin-like glycoproteins that tether sporozoites of Cryptosporidium parvum to the inner surface of the oocyst wall. Eukaryot Cell 9:84–96. doi: 10.1128/EC.00288-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Bushkin GG, Motari E, Carpentieri A, Dubey JP, Costello CE, Robbins PW, Samuelson J. 2013. Evidence for a structural role for acid-fast lipids in oocyst walls of Cryptosporidium, Toxoplasma, and Eimeria. mBio 4:e00387-13. doi: 10.1128/mBio.00387-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Kuhlenschmidt TB, Rutaganira FU, Long S, Tang K, Shokat KM, Kuhlenschmidt MS, Sibley LD. 2016. Inhibition of calcium-dependent protein kinase 1 (CDPK1) in vitro by pyrazolopyrimidine derivatives does not correlate with sensitivity of Cryptosporidium parvum growth in cell culture. Antimicrob Agents Chemother 60:570–579. doi: 10.1128/AAC.01915-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
- 41.Brown KM, Long SJ, Sibley LD. 2017. Plasma membrane association by N-acylation governs PKG function in Toxoplasma gondii. mBio 8:e00375-17. doi: 10.1128/mBio.00375-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Zhang X, Kim CY, Worthen T, Witola WH. 2018. Morpholino-mediated in vivo silencing of Cryptosporidium parvum lactate dehydrogenase decreases oocyst shedding and infectivity. Int J Parasitol 48:649–656. doi: 10.1016/j.ijpara.2018.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Pawlowic MC, Vinayak S, Sateriale A, Brooks CF, Striepen B. 2017. Generating and maintaining transgenic Cryptosporidium parvum parasites. Curr Protoc Microbiol 46:20B.2.1–20B.2.32. doi: 10.1002/cpmc.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All of the data are found in the manuscript or supplemental material.